Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

used in determining our GAAP diluted net income  (loss) per share. A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release. The Company believes that its presentation of historical non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. These historical non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles.

Research and Development ProgramsViroPharma is investing in research and development programs to ensure growth for the future.  The current pipeline includes programs in various stages of clinical and pre-clinical development focused on rare diseases and serious unmet medical needs.

  • Subcutaneous administration of Cinryze – In December 2012, we initiated a Phase 2b double blind, multi-center, dose ranging study to evaluate the safety and efficacy of subcutaneous administration of in combination with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) in adolescents and adults with HAE for prevention of HAE attacks.  We expect to complete enrollment in this study during the first week of May, 2013.
  • New uses for C1 INH - We are investigating potential new uses for our C1 esterase inhibitor product with a goal of pursuing additional indications in patient populations with other C1 INH mediated diseases.  To that end, we are supporting investigator-initiated studies (IISs) evaluating C1 INH as a treatment for patients with Neuromyelitis Optica (NMO) and Autoimmune Hemolytic Anemia (AIHA); both of these studies were initiated in 2012. We are also conducting a clinical trial in Antibody-Mediated Rejection (AMR) post renal transplantation and are evaluating the pote
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Participate in Two December Healthcare Investor Conferences
    2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
    3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    8. WuXi PharmaTech Announces Third-Quarter 2011 Results
    9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    10. Spherix Announces Third Quarter Financial Results
    11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
    (Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
    (Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
    (Date:7/29/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today ... Financial Officer has resigned.  The Company has hired ... retired in December 2014, as full time interim CFO ... Andy Ashworth began his employment ... smooth transition.  Andy was the Company,s CFO from September ...
    Breaking Biology Technology:GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
    ... Calif., Aug. 30 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ... Executive Officer of TorreyPines, will present at the NewsMakers ... September 6th at,3:00 p.m., Eastern Time. A webcast ... can,access the webcast at: http://www.torreypinestherapeutics.com . An archived,version ...
    ... BRISBANE, Calif., Aug. 30 InterMune, Inc.,(Nasdaq: ITMN ... Chief,Executive Officer of InterMune, will present at the Thomas ... 3:50 p.m. EDT. Mr.,Welch will also present at the ... on September 11, 2007 at 3 p.m. EDT. ...
    ... Australia, Aug. 30 Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: ... present at the Thomas Weisel,Partners Healthcare Conference at The ... 2007 at 9:10 AM EDT. The audio presentation ... the,Company,s website at http://www.progen-pharma.com . A replay of ...
    Cached Biology Technology:InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences 2
    (Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... it has filed provisional patent 62/198989 for ... invention highlights a method to advance crypto-currencies such as ... introducing a common, uniform way to manage all payments.  ...
    (Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
    (Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
    Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
    ... Mellon University researchers have identified a new anticonvulsant compound ... epilepsy. The findings are published in the March issue ... The research discovery builds on previous work identifying ... with seizure disorders, a potassium channel known as the ...
    ... holes in the limestone of the ocean floor using teeth ... their secrets, which might give engineers insights into creating ever-sharp ... fit their globular bodies using their five teeth, which, like ... continue to grow on the other end throughout the animals, ...
    ... May 1, 2009 -- With each passing year, the human ... created a wide ranging strain on our water and soil ... to address the issue of food security. One way that ... modification of seeds, both as a method of improving crop ...
    Cached Biology News:Drug prevents seizure progression in model of epilepsy 2True grit 2Food security: It starts with seed 2
    Request Info...
    ... Multidrop Combi is a new generation dispenser ... dispensing with the proven performance of the existing ... cover large volume area starting from 500 nl ... the range. ,It is optimized for ...
    ... offers lower consumption of reagents and ... The Multidrop 384 is an automated ... microvolume dispensing into 384- and 96-well ... It can easily switch from 96- ...
    MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
    Biology Products: